<DOC>
	<DOCNO>NCT00045513</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combine UCN-01 fludarabine treat patient relapsed refractory chronic lymphocytic leukemia lymphocytic lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Chronic Lymphocytic Leukemia Lymphocytic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall response rate patient relapse refractory chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma treat UCN-01 fludarabine . - Assess molecular change CLL cell peripheral blood patient treat regimen . - Determine progression-free overall survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter , dose-escalation study UCN-01 . Patients receive UCN-01 IV 3 hour day 1 fludarabine IV 30-60 minute day 1-5 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos UCN-01 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 18-46 additional patient receive UCN-01 fludarabine recommend phase II dose . PROJECTED ACCRUAL : A total 12 patient accrued phase I portion study within 6 month . A total 18-46 patient accrue phase II portion study within 9-23 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm chronic lymphocytic leukemia ( CLL ) Bcell small lymphocytic lymphoma ( SLL ) CLL define : Persistent lymphocytosis great 5,000/mm^3 CD19/CD5/CD23 positive Kappa lambda light chain restriction Refractory disease progression 1 2 prior treatment regimen Retreatment oral chlorambucil allow consider second regimen At least one chlorambucil treatment must 3 month longer At least 4 course cyclophosphamide , vincristine , prednisone without doxorubicin allow Patients may receive prior fludarabine first secondline therapy evidence least partial response time progression initial fludarabine therapy least 12 month No CNS involvement lymphoma PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 3 month Hematopoietic See Disease Characteristics Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 No autoimmune hemolytic anemia thrombocytopenia secondary CLL SLL require ongoing therapy prednisone immunosuppressive agent Hepatic Bilirubin normal AST ALT great 2.5 time upper limit normal Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Pulmonary DLCO great 60 % predict FEV_1 great 70 % predict No significant underlie pulmonary disease Other No malignancy within past 5 year except adequately treat basal cell skin cancer carcinoma situ cervix No insulindependent diabetes mellitus No uncontrolled concurrent illness No ongoing active infection No preexist peripheral neuropathy grade 2 great No psychiatric illness social situation would preclude study compliance No prior allergic reaction compound similar chemical biological composition UCN01 agent study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy recover Endocrine therapy See Hematopoietic Radiotherapy No prior mediastinal radiation At least 4 week since prior radiotherapy recover Surgery Not specify Other No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>